Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study

被引：0

作者：

Aldoss, Ibrahim ^{[1
]}

Ribera, Josep-Maria ^{[2
]}

Kantarjian, Hagop ^{[3
]}

Montesinos, Pau ^{[4
]}

Leonard, Jessica T. ^{[5
]}

Gomez-Almaguer, David ^{[6
]}

Baer, Maria R. ^{[7
]}

Gambacorti-Passerini, Carlo ^{[8
]}

McCloskey, James ^{[9
]}

Minami, Yosuke ^{[10
]}

Papayannidis, Cristina ^{[11
]}

Rocha, Vanderson ^{[12
]}

Rousselot, Philippe ^{[13
]}

Vachhani, Pankit ^{[14
]}

Wang, Eunice S. ^{[15
]}

Hennessy, Meliessa ^{[16
]}

Patel, Niti ^{[16
]}

Vorog, Alexander ^{[16
]}

Wang, Bingxia ^{[16
]}

Jabbour, Elias ^{[17
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Hosp Badalona Germans Trias & Pujol, ICO Badalona, Josep Carreras Leukaemia Res Inst, Badalona, Spain

[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[4] Hosp Univ & Politecn La Fe Valencia, Valencia, Spain

[5] Oregon Hlth & Sci Univ, Portland, OR USA

[6] UANL, Hosp Univ Dr Jose Eleuterio Gonzalez, Monterrey, Mexico

[7] Univ Maryland, Dept Med, Sch Med, Baltimore, MD USA

[8] Univ Milano Bicocca, Monza, Italy

[9] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[11] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[12] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[13] Univ Versailles Paris Saclay, Ctr Hosp Verailles, UMR1184, Versailles, France

[14] Univ Alabama Birmingham, Birmingham, AL USA

[15] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[16] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179537

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
Gambacorti-Passerini, Carlo
Cortes, Jorge E.
Lipton, Jeff H.
Dmoszynska, Anna
Wong, Raymond S.
Rossiev, Victor
Pavlov, Dmitri
Marchant, Karin Gogat
Duvillie, Ladan
Khattry, Navin
Kantarjian, Hagop M.
Bruemmendorf, Tim H.
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (10) : 947 - 953
[32] A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis
Zheng, Zhong
Wang, Li
Cheng, Shu
Xu, Pengpeng
Zhao, Weili
BLOOD, 2019, 134
[33] Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (PH plus ALL).
Ottmann, OG
Wassmann, B
Pfeifer, H
Goekbuget, N
Bug, G
Brueck, P
Binckebanck, A
Gschaidmeier, H
Hoelzer, D
BLOOD, 2004, 104 (11) : 197A - 197A
[34] Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph plus ) acute lymphoblastic leukemia (ALL)
Ravandi, F.
Faderl, S.
Thomas, D. A.
Brown, D.
Garris, R.
Borthakur, G.
Ferrajoli, A.
Cortes, J. E.
Kantarjian, H. M.
O'Brien, S. M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[35] Imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia chronic phase: A comparative study
Jacob, L. A.
Bapsy, P. P.
Govindbabu, K.
Lokanatha, D.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[36] Romiplostim for the Treatment of Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia: Subgroup Analysis from a Phase 2 Study
Newland, Paneladrian C.
Viallard, Jean-Francois
Lopez Fernandez, Maria Fernanda
Eisen, Melissa Jeanne
Saad, Hossam A.
Hippenmeyer, Jane
Godeau, Bertrand
BLOOD, 2021, 138
[37] Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
Kenshi Suzuki
Ashutosh D. Wechalekar
Kihyun Kim
Chihiro Shimazaki
Jin Seok Kim
Takayuki Ikezoe
Chang-Ki Min
Fude Zhou
Zhen Cai
Xiaonong Chen
Shinsuke Iida
Nagaaki Katoh
Tomoaki Fujisaki
Ho-Jin Shin
NamPhuong Tran
Xiang Qin
Sandra Y. Vasey
Brenda Tromp
Brendan M. Weiss
Raymond L. Comenzo
Efstathios Kastritis
Jin Lu
Annals of Hematology, 2023, 102 : 863 - 876
[38] Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
Suzuki, Kenshi
Wechalekar, Ashutosh D. D.
Kim, Kihyun
Shimazaki, Chihiro
Kim, Jin Seok
Ikezoe, Takayuki
Min, Chang-Ki
Zhou, Fude
Cai, Zhen
Chen, Xiaonong
Iida, Shinsuke
Katoh, Nagaaki
Fujisaki, Tomoaki
Shin, Ho-Jin
Tran, NamPhuong
Qin, Xiang
Vasey, Sandra Y. Y.
Tromp, Brenda
Weiss, Brendan M. M.
Comenzo, Raymond L. L.
Kastritis, Efstathios
Lu, Jin
ANNALS OF HEMATOLOGY, 2023, 102 (4) : 863 - 876
[39] ASC4START: A Phase 3b, open-label, randomized study of asciminib versus nilotinib in patients with newly diagnosed Ph plus Chronic Myelogenous Leukemia in Chronic Phase
Bruemmendorf, T. H.
Saussele, S.
Mahon, F. -X
Le Coutre, P.
Stegelmann, F.
Haenel, M.
Pilipovic, V
Gu, E.
Schuld, P.
Hochhaus, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 280 - 280
[40] Subcutaneous Daratumumab (DARA SC) plus Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study
Suzuki, Kenshi
Wechalekar, Ashutosh D.
Kim, Kihyun
Shimazaki, Chihiro
Kim, Jin Seok
Ikezoe, Takayuki
Min, Chang-Ki
Zhou, Fude
Iida, Shinsuke
Katoh, Nagaaki
Fujisaki, Tomoaki
Shin, Ho-Jin
Tran, NamPhuong
Qin, Xiang
Vasey, Sandra Y.
Tromp, Brenda
Weiss, Brendan M.
Vermeulen, Jessica
Comenzo, Raymond L.
Kastritis, Efstathios
BLOOD, 2020, 136

← 1 2 3 4 5 →